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Abstract
Signaling and post-transcriptional gene control are both critical for the regulation of 
pluripotency1,2, yet how they are integrated to influence cell identity remains poorly understood. 
LIN28 (also known as LIN28A), a highly conserved RNA-binding protein (RBP), has emerged as 
a central post-transcriptional regulator of cell fate through blockade of let-7 microRNA (miRNA) 
biogenesis and direct modulation of mRNA translation3. Here we show that LIN28 is 
phosphorylated by MAPK/ERK in pluripotent stem cells (PSCs), which increases its levels via 
post-translational stabilization. LIN28 phosphorylation had little impact on let-7 but enhanced 
LIN28’s effect on its direct mRNA targets, revealing a mechanism that uncouples LIN28’s let-7-
dependent and independent activities. We have linked this mechanism to the induction of 
pluripotency by somatic cell reprogramming and the transition from naïve to primed pluripotency. 
Collectively, our findings indicate that MAPK/ERK directly impacts LIN28, defining an axis that 
connects signaling, post-transcriptional gene control, and cell fate regulation.
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The control of pluripotency requires precise coordination of multiple gene regulatory 
mechanisms, yet how this is orchestrated at the molecular level remains incompletely 
understood. Signaling has a key role in this network1, with the MAPK/ERK pathway 
holding a particularly prominent place, since its activity primes PSCs for lineage 
commitment4 whereas its inhibition is essential for the maintenance of a “naïve” state of 
pluripotency5. The effects of MAPK – and signaling pathways in general – are typically 
associated with downstream transcriptional mechanisms, while less is known about their 
integration with the post-transcriptional gene regulatory machinery1,2. Gaining insights into 
the latter is critical, as post-transcriptional mechanisms play a major role in the control of 
cell identity, especially in guiding transitions between cell fates2.
LIN28, a highly conserved RBP, is a master post-transcriptional regulator of cell fate that 
controls embryonic development from C. elegans to mammals3,6. It supports the 
proliferative and metabolic capacities of PSCs, promotes reprogramming to pluripotency, 
and facilitates the transition from naïve to primed pluripotency3,7–9. Its effects are mediated 
through blockade of the biogenesis of the let-7 miRNA family10–13, and through direct 
translational enhancement or suppression of select mRNAs9,14–18.
To gain insight into how LIN28 is integrated with the pluripotency signaling network, we 
investigated the role of LIN28 phosphorylation. Global phosphoproteomic studies of human 
embryonic stem cells (hESCs) had identified several putative phosphosites in LIN2819,20. To 
validate their conservation between human and mouse, we employed a targeted 
phosphoproteomics strategy in mouse ESCs (mESCs) (Supplementary Fig. 1a–c). We were 
able to map four phosphosites, two of which, S184 and S200, were confidently assigned to 
specific serine residues (Supplementary Table 1). Combining our data and prior results19,20, 
we generated a comprehensive profile of LIN28 phosphorylation in PSCs (Fig. 1a).
To identify kinases that phosphorylate LIN28, we interrogated the LIN28 amino acid 
sequence for conserved kinase recognition motifs (Supplementary Fig. 1d). Since we noticed 
members of the MAPK family as predicted kinases for S200, we decided to further 
investigate this phosphorylation event (Fig. 1b). We generated an antibody reactive against 
phospho-S200 and validated its specificity with a phospho-null LIN28 mutant, in which 
S200 is mutated to alanine (S200A) (Fig. 1c). Using this antibody, we profiled a panel of 
human PSCs, all of which exhibited LIN28 (S200) phosphorylation, suggesting that the 
latter is a common molecular feature of PSCs (Supplementary Fig. 1e).
To identify the particular MAPK responsible for S200 phosphorylation, we performed a 
targeted inhibitor screen in human embryonal carcinoma cells (hECCs). We used selective 
inhibitors of the major MAPKs, including MEK/ERK, p38 MAPK, JNKs, CDKs, and 
GSK3β, as well as mTOR, an unrelated proline-directed kinase. Of those, only the 
MEK/ERK inhibitor, PD0325901, consistently reduced S200 phosphorylation under the 
tested conditions (Fig. 1d). We then serum-starved hECCs and subjected them to short-term 
treatment with phorbol myristate acetate (PMA), which activates MAPK/ERK signaling. 
S200 phosphorylation was induced, corroborating the inhibitor data (Fig. 1e). Pre-treatment 
with the MEK/ERK inhibitor but not with an inhibitor of a different MAPK, p38 MAPK, 
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abrogated the PMA-induced phosphorylation of LIN28, indicating that the PMA effects are 
mediated via ERK (Fig. 1e).
To confirm this conclusion, we also expressed wild-type, constitutively active (R4F), or 
kinase-dead (K97M) versions of MEK121 in 293T cells stably expressing a LIN28 ORF and 
subjected them to serum starvation. As expected, only the R4F mutant was able to activate 
ERK and maintain LIN28 phosphorylation under these conditions (Fig. 1f). Lastly, we 
serum-starved hECCs and added back serum or treated them with fibroblast growth factor 
(FGF) or epidermal growth factor (EGF), physiologically relevant cues that induce ERK 
signaling. All three treatments led to increased LIN28 phosphorylation (Fig. 1g). 
Collectively, our results demonstrate that ERK phosphorylates LIN28 on S200 in response to 
mitogenic stimuli.
Next, we explored whether S200 phosphorylation affects LIN28 function. Intriguingly, we 
noticed that pre-treatment with the phosphatase inhibitor Calyculin A led to increased 
LIN28 abundance in our mass spectrometry samples (Supplementary Fig. 1b). Western blot 
analysis confirmed an approximately 30% increase of LIN28 protein (Fig. 2a). A similar 
effect was observed in the MEK1 overexpression experiments (Fig. 1f), suggesting that 
ERK-mediated phosphorylation may stabilize LIN28 protein. To test this hypothesis, we 
treated hECCs with PMA for three hours, which led to a 30% increase in LIN28 protein, 
without concordant mRNA changes (Fig. 2b). Conversely, a 48-hour treatment with the 
MEK/ERK inhibitor resulted in a one-third decrease of LIN28 at the protein but not mRNA 
level (Fig. 2c and Supplementary Fig. 2a), overall supporting our hypothesis.
To further explore this question, we generated stable isogenic 293T and HeLa cell lines 
expressing wild-type, phospho-mimetic (S200D or S200E), or phospho-null (S200A) 
LIN28, in which serine phosphorylation is mimicked or abrogated by substitution with 
aspartate/glutamate or alanine, respectively. While the phospho-mimetics showed 50–100% 
increase in protein levels, the phospho-null exhibited 40–50% decrease, without 
corresponding mRNA changes (Fig. 2d). These data indicate that the observed effects on 
LIN28’s protein levels are post-translational and specifically mediated through the ERK 
target site in LIN28.
Lastly, we performed cycloheximide chase experiments in hECCs to track the decay kinetics 
of endogenous pLIN28 (S200) and total LIN28. While the total protein decayed with an 
estimated half-life of 12 hours, the phosphoprotein remained stable for the 24-hour course of 
the experiment (after an initial treatment-induced phosphorylation spike), suggesting that 
pLIN28 has a longer half-life and is thus relatively more stable (Fig. 2e). We then conducted 
analogous experiments using the isogenic HeLa cells expressing LIN28 phosphorylation 
mutants, which showed that the mimetic (S200E) and null (S200A) mutants decay slower 
and faster, respectively, compared to wild-type LIN28 (Fig. 2f). As these LIN28 variants are 
under doxycycline-control, we also withdrew doxycycline and tracked their decay kinetics in 
an unperturbed way, which confirmed the cycloheximide chase results (Fig. 2g). Taken 
together, the above data indicate that ERK-mediated phosphorylation stabilizes LIN28 post-
translationally by increasing its protein half-life.
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We then examined the effect of LIN28 phosphorylation on its downstream targets. First, we 
assessed let-7 regulation. We performed let-7 measurements in hECCs after a 48-hour 
treatment with the MEK/ERK inhibitor, which revealed a lack of statistically significant 
change in let-7 levels (Supplementary Fig. 2b). These data suggested that the ~30% 
reduction of LIN28 abundance due to loss of phosphorylation was insufficient to 
consistently affect let-7 processing. In support of this observation, ~30% knockdown of 
LIN28 protein yielded similar results (Supplementary Fig. 3a). To further address this 
question, we derived individual clones of HeLa cells stably expressing wild-type LIN28 at 
different levels. LIN28 protein expression equivalent to about 50% of its native level in 
hECCs achieved saturation of let-7 suppression, confirming our earlier conclusion 
(Supplementary Fig. 4a). To specifically assess the role of S200 phosphorylation, we also 
measured let-7 levels in the isogenic HeLa cells expressing wild-type or phospho-null 
(S200A) LIN28. As expected, the two LIN28 variants achieved comparable let-7 
suppression despite the consistently lower protein levels of the S200A mutant 
(Supplementary Fig. 4b,c).
We then performed RNA immunoprecipitation (RIP) experiments in hECCs stably 
overexpressing wild-type or phospho-mimetic (S200D) LIN28 (Fig. 3a), followed by qRT-
PCR measurement of pri/pre-let-7 association. The two proteins precipitated comparable 
amounts of most pri/pre-let-7s analyzed, consistent with lack of effect on let-7 processing 
(Fig. 3b). In line with these results, mature let-7 levels were also unchanged in the mimetic 
relative to the wild-type cells (Fig. 3c). Overall, our data from multiple assays demonstrate 
that LIN28 phosphorylation does not have a significant impact on let-7.
Next, we explored the effect of LIN28 phosphorylation on its mRNA targets. To do this on a 
transcriptome-wide scale, we performed RNA immunoprecipitation coupled with mRNA-
seq (RIP-seq) of the wild-type and phospho-mimetic (S200D) LIN28 in hECCs. When 
normalized to the amount of immunoprecipitated LIN28, the two proteins showed highly 
similar mRNA binding profiles, indicating that they have comparable affinities to their 
mRNA targets (Fig. 3d). However, when normalized to cell number, a follow-up qRT-PCR 
analysis of representative mRNAs revealed a stoichiometric increase in mRNA association 
that was specific to the LIN28 targets (Fig. 3e). Of note, similar results were obtained with 
the S200E mutant in the isogenic HeLa cells (Supplementary Fig. 4f,g). Overall, these data 
suggest that the phospho-mimetic mutants have comparable mRNA binding affinities to the 
wild-type protein but, due to their higher abundance per cell, associate with a greater amount 
of the same targets.
To further support this conclusion, we also performed complementary analysis in the 
isogenic HeLa cells expressing wild-type or phospho-null (S200A) LIN28. Consistent with 
its reduced protein abundance, the phospho-null LIN28 reproducibly precipitated lower 
amount of RNA per cell relative to the wild-type construct, which was proportional to their 
respective protein levels (Supplementary Fig. 4d). However, when normalized to the amount 
of immunoprecipitated LIN28, the two constructs showed aligned mRNA binding profiles, 
corroborating the hECC data (Supplementary Fig. 4e).
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Lastly, we wanted to confirm that the changes in mRNA binding per cell affect their cognate 
protein expression, as LIN28 is known to modulate mRNA translation9,14–18. We validated a 
set of previously established LIN28 mRNA targets by assessing their mRNA and protein 
levels after ~30% LIN28 knockdown in hECCs. As expected, mRNA levels were unaffected 
while protein levels decreased (for RPS13) or increased (for RPL23, NDUFB3, NDUFB8, 
and NDUFB10), in agreement with their reported LIN28-dependent translational 
enhancement and suppression, respectively (Supplementary Fig. 3b,c)9,14,15. We then 
performed qRT-PCR and Western blot analyses of these targets in the hECCs expressing 
wild-type or phospho-mimetic (S200D) LIN28. While the mRNA levels were unchanged, 
protein levels were altered in the mimetic relative to the wild-type construct, consistent with 
stronger translational activity of LIN28 (Fig. 3f,g). Importantly, these protein changes were 
in the opposite direction to the ones observed after LIN28 depletion and involved both 
positively and negatively regulated targets, suggesting that they reflect LIN28’s overall 
translational activity rather than only its translation-promoting or suppressing function. 
Together, our results indicate that ERK-mediated LIN28 phosphorylation has little impact on 
let-7 but enhances LIN28’s regulation of its mRNA targets, thereby acting as a mechanism 
for uncoupling of LIN28’s let-7-dependent and independent activities.
Given these molecular findings, we wondered if this mechanism regulates LIN28’s function 
in guiding cell fate transitions. As LIN28 potently promotes the induction of pluripotency 
via somatic cell reprogramming7, we performed factor-based reprogramming using wild-
type, phospho-null (S200A), or phospho-mimetic (S200D) LIN28 in combination with 
OCT4, SOX2 and NANOG. Consistent with our earlier data, the S200A and S200D mutants 
showed lower and higher protein expression than the wild-type, respectively, without 
concordant mRNA changes (Fig. 4a). The altered LIN28 protein abundance further appeared 
insufficient to differentially affect let-7 (Fig. 4b). Importantly, however, the S200A and 
S200D LIN28 led to approximately 50% decreased or increased reprogramming efficiency, 
respectively, indicating that S200 phosphorylation and its effect on LIN28 have a substantial 
role in the induction of pluripotency (Fig. 4c).
We then addressed LIN28’s function in ESCs. Since ERK5 and LIN288,9 control the 
transition from naïve to primed pluripotency, we explored the regulation of LIN28 levels in 
mESCs cultured in serum/LIF versus dual-inhibitor/LIF (2i/LIF) conditions. Consistent with 
previous reports8,9, LIN28 levels were reduced both at the protein and mRNA level in the 
2i/LIF culture (Fig. 4d). To examine whether ERK-dependent post-translational control 
contributes to this reduction, we performed inhibitor dropout experiments. Short-term 
removal of the MEK/ERK inhibitor – but not the GSK3β inhibitor – led to a ~30% increase 
in LIN28 protein but not mRNA, supporting an ERK-mediated protein stabilization model 
(Fig. 4e). To confirm that S200 phosphorylation is involved, we replaced endogenous LIN28 
with wild-type, phospho-mimetic (S200D), or phospho-null (S200A) LIN28 by expressing 
respective ORF constructs into mESCs with knocked out LIN28A/B loci. Consistent with 
our earlier data, the mimetic and null maintained higher and lower protein levels (when 
cultured in serum), respectively, without analogous mRNA changes (Fig. 4f). We then 
performed clonogenic assays upon transfer from 2i/LIF to serum/LIF and assessed the 
alkaline phosphatase (AP) staining pattern of colonies emerging in the serum/LIF culture, 
which is characterized by a mix of compact, uniformly AP-positive, naïve-like (“solid”) 
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colonies and larger, heterogeneously AP-stained, more primed (“mixed”) colonies8. The 
S200D mutant showed a reproducibly lower fraction of solid colonies while the S200A 
exhibited a higher fraction relative to wild-type LIN28, demonstrating that the higher LIN28 
protein level mediated by S200 phosphorylation enhances LIN28’s function in promoting 
the transition from naïve to primed pluripotency (Fig. 4g). Together, our reprogramming and 
ESC data demonstrate that LIN28 phosphorylation contributes to the regulation of 
pluripotency transitions.
In sum, our results indicate that LIN28 phosphorylation by MAPK/ERK serves as a 
molecular link between signaling, post-transcriptional gene regulation, and cell fate control. 
While ERK is known to impact numerous pluripotency transcription factors22, LIN28 is an 
RBP and thus represents a distinct mechanism by which ERK signaling regulates gene 
expression and cell identity. Of note, ERK has also been suggested to regulate LIN28 
transcriptionally8,23, so it may exert dual regulation on LIN28 to ensure timely and robust 
control of LIN28 levels. Given the repertoire of pluripotency-associated RBPs24 and a recent 
link between ERK and the RBP Brf1 in mESCs25, other RBPs may be similarly regulated by 
ERK to modulate cell fate.
Adding to prior findings8,9, the ERK-LIN28 coupling reported here further implicates 
LIN28 as a “priming” factor and suggests that its activity is particularly relevant in guiding 
transitions between cell states, closely matching its primordial function in C. elegans6. Given 
the critical role of timing for these transitions, post-translational mechanisms are well-suited 
to control LIN28 function. As we and others have mapped multiple phosphorylation sites on 
LIN28 (Fig. 1a), additional kinase pathways may also regulate LIN28. Other post-
translational modifications, namely acetylation26 and methylation27, have also been reported 
to control LIN28, so the latter appears to integrate both extrinsic and intrinsic signals, in line 
with its role as a key hub of post-transcriptional gene regulation.
Finally, the mechanism described herein highlights the role of LIN28’s let-7-independent 
activities in cell fate regulation and may also explain the intriguing observation that LIN28’s 
let-7-independent functions precede its let-7-mediated ones during cell differentiation and 
organismal development28,29. A gradual, controlled decrease in LIN28 levels, initiated by 
protein destabilization, may allow for disengagement of its mRNA targets prior to effects on 
let-7.
METHODS
Plasmids
For stable expression, FLAG-LIN28A was subcloned in the pBabe-Puro (retroviral) or pSin-
Puro (lentiviral) vectors. pBabe-Puro was a gift from H. Land, J. Morgenstern, and R. 
Weinberg (Addgene plasmid #1764)30, and pSin was a gift from J. Thomson (Addgene 
plasmid #16578)7. Phospho-mimetic and phospho-null mutants were generated using the 
QuikChange Lightning site-directed mutagenesis kit (Agilent Technologies), as per 
manufacturer’s protocol. pMCL-HA-MEK1 wild-type, constitutively active (R4F), and 
kinase-dead (K97M) plasmids were gifts from N. Ahn (Addgene plasmids #48808, 40810, 
40811)21.
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Cell Culture
iLIN28A31, v6.532, and LIN28A/B KO33 mESCs were maintained on irradiated CF1 MEFs 
(GlobalStem) in mESC medium (DMEM, 15% FBS, 1 U/ml Penicillin, 1 µg/ml 
Streptomycin, 2 mM L-glutamine, 0.1 mM NEAA, 0.1 mM BME, 1,000 U/ml LIF). hESCs 
(CHB6, NIH#0006), MSC-iPSCs34, and BJ1-iPSCs34 were maintained in hESC medium 
(DMEM/F12, 20% KOSR, 1 U/ml Penicillin, 1 µg/ml Streptomycin, 2 mM L-glutamine, 0.1 
mM NEAA, 0.1 mM BME, 4 ng/ml FGF). PA1 (ATCC# CRL-1572), NCCIT (ATCC# 
CRL-2073), HeLa (ATCC# CCL-2), and 293T cells were maintained in DMEM/10% FBS. 
293T(RMCE) cells were a gift from E. Makeyev; LIN28-expressing lines were generated 
following published protocols35. HeLa Flp-In cell lines were generated as described 
previously36. 2i/LIF culture was performed following published protocols5. No cell lines 
used in this study were found in the database of commonly misidentified cell lines that is 
maintained by ICLAC and NCBI Biosample. The cell lines were not authenticated. The cell 
lines were tested mycoplasma-negative.
Transfections
For plasmid transfections, 293T cells were seeded at 4 × 105 cells/well in 6-well plates, 
transfected with 2 ug respective plasmid 16–20 hours later using X-tremeGENE 9 (Roche), 
and analyzed after another 48 hours. For siRNA transfections, PA1 cells were seeded at 3 × 
105 cells/well in 6-well plates, transfected with 0.25 pmol siRNA 16–20 hours later using 
Lipofectamine RNAiMAX (Invitrogen), and harvested by trypsinization after another 96 
hours. The following siRNAs were used: siNC (Ambion #4390843); siLIN28A (Ambion 
#4392420-s36195).
Viral Production and Stable Cell Line Generation
Viral production was carried out as described previously9. Transgenic PA1 and HeLa cells 
were generated by transduction with unconcentrated viral supernatant and selection with 1 
ug/ml Puromycin. HeLa-LIN28A clones were derived by isolation and expansion of single 
cells from a heterogeneous pool of stable transductants. For transgenic mESC generation, 
lentivirus was concentrated using the Lenti-X Concentrator (Clontech) and used for 
transduction in 2i/LIF medium, followed by selection with 1 ug/ml Puromycin.
Drug Treatments
Drugs used were: Calyculin A (Cell Signaling), Torin1 (Tocris), PD0325901 (Stemgent), 
SB203580 (Invivogen), SP600125 (Sigma), Kenpaullone (Sigma), LY294002 (Cell 
Signaling), bFGF (Gemini), EGF (Peprotech), PMA (Cell Signaling), CHX (Sigma), and 
Doxycycline (Sigma). Treatment conditions are described in detail in the text.
Affinity Purification
For mass spectrometry analysis, iLIN28A mESCs were treated with: (i) 1 µg/ml 
Doxycycline (Sigma) for 48 hours to induce FLAG-LIN28A expression, and (ii) 100 nM 
Calyculin A (Cell Signaling) for 30 minutes immediately prior to harvest to enrich for 
phosphorylation events. Cells were harvested in cold PBS and immediately lysed in M2 lysis 
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) containing 
Tsanov et al. Page 7
Nat Cell Biol. Author manuscript; available in PMC 2017 June 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2X protease and phosphatase inhibitors (Pierce). FLAG-tagged LIN28 variants were purified 
using the anti-FLAG M2 affinity gel following the manufacturer’s specifications (Sigma).
Mass Spectrometry
Affinity purified proteins were separated on a 4–20% polyacrylamide gel (Bio-Rad) and 
visualized using the Bio-Safe Coomassie Stain (Bio-Rad). The band containing FLAG-
LIN28A was excised and treated with dithiotriethol to reduce disulfide bonds and 
iodoacetamide to alkylate cysteines. In-gel digestion of the protein was performed with 
trypsin or chymotrypsin. The resulting peptides were extracted from the gel and analyzed by 
liquid chromatography tandem mass spectrometry (LC-MS/MS), as described previously37. 
All peptide matches were filtered based on mass accuracy, tryptic state (for trypsin), and 
XCorr, and confirmed by manual inspection. The reliability of site-localization of 
phosphorylation events was evaluated using the Ascore algorithm38.
Antibody Generation
Human and mouse-reactive pLIN28(S200) rabbit polyclonal antibodies were produced by 
immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding 
S200 of human or mouse LIN28A, respectively. Antibodies were purified by protein A and 
peptide affinity chromatography. The human-reactive antibody was generated by Cell 
Signaling (Danvers, MA) and the mouse-reactive antibody by GenScript (Piscataway, NJ).
Western Blot
Cells were lysed in RIPA buffer containing protease and phosphatase inhibitors (Pierce). 
Proteins were separated on a 4–20% polyacrylamide gel (Bio-Rad) and transferred to a 
methanol-activated PVDF membrane (Millipore). The membrane was blocked for 30–60 
minutes in 3%BSA/PBST (chemiluminescent blots) or 3%BSA/PBS (fluorescent blots), and 
probed with primary antibodies at 4°C overnight. Secondary antibody incubation was 
performed at room temperature for 1–2 hours. Protein levels were detected using the 
SuperSignal West Pico and Femto Luminol reagents (Thermo Scientific) or the Odyssey 
CLx near-infrared fluorescence imaging system (LI-COR). Primary antibodies used were: 
anti-pLIN28(S200) (generated as described above; 1:1,000), anti-LIN28A (Cell Signaling 
#3978; 1:1,000), anti-α/β-tubulin (Cell Signaling #2148; 1:1,000), anti-pERK1/2 (Sigma 
E7028; 1:1,000), anti-ERK1/2 (Cell Signaling #4695, clone 137F5; 1:1,000), anti-FLAG 
(Sigma F3165, clone M2; 1:1,000), anti-Actin (Santa Cruz sc-1616; 1:2,000), anti-HA 
(Sigma H6533, clone HA-7; 1:1,000), anti-RPS13 (Abcam ab104862; 1:1,000), anti-RPL23 
(Proteintech #16086-1-AP; 1:1,000), anti-NDUFB3 (Abcam ab55526; 1:1,000), anti-
NDUFB8 (Abcam ab110242, clone 20E9DH10C12; 1:1,000), anti-NDUFB10 (Proteintech 
#15589-1-AP; 1:1,000). Secondary antibodies used were: for chemiluminescence, HRP-
conjugated anti-rabbit IgG (GE Healthcare NA934, 1:2,000), anti-mouse IgG (GE 
Healthcare NA931; 1:2,000), and anti-goat IgG (Santa Cruz sc-2020; 1:2,000); for 
fluorescence, IRDye 680RD anti-rabbit IgG (LI-COR #925-68071; 1:20,000), IRDye 
800CW anti-mouse IgG (LI-COR #925-32210; 1:20,000), and IRDye 680RD anti-goat IgG 
(LI-COR #925-68074; 1:20,000). Quantifications were performed using ImageJ 
(chemiluminescent blots) or Image Studio for Odyssey CLx (fluorescent blots) (LI-COR).
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Quantitative RT-PCR
Total RNA was isolated using Trizol (Invitrogen) combined with miRNeasy columns 
(Qiagen). 100–250 ng RNA were reverse-transcribed using the miScript II RT kit (Qiagen) 
and subjected to miScript miRNA assays (Qiagen) or standard mRNA assays. miRNA and 
mRNA expression was measured by SYBR Green quantitative PCR using the ΔΔCt method. 
U6 and β-actin were used for normalization of miRNA and mRNA measurements, 
respectively. Primers used were: hLIN28A (F: GAGCATGCAGAAGCGCAGATCAAA; R: 
TATGGCTGATGCTCTGGCAGAAGT); FLAG-hLIN28A (F: 
ATGACGACAAGGGCTCCG; R: CGCACGTTGAACCACTTACA); hACTB (F: 
AGAAGGATTCCTATGTGGGCG; R: CATGTCGTCCCAGTTGGTGAC); mLin28a (F: 
AGGCGGTGGAGTTCACCTTTAAGA; R: AGCTTGCATTCCTTGGCATGATGG); 
mActB (F: CAGAAGGAGATTACTGCTCTGGCT; R: 
TACTCCTGCTTGCTGATCCACATC); hRPS13 (F: TCCCAGTCGGCTTTACCCTAT; R: 
CAGGATTACACCGATCTGTGAAG); hRPL23 (F: TCCTCTGGTGCGAAATTCCG; R: 
CGTCCCTTGATCCCCTTCAC); hNDUFB3 (F: GCTGGCTGCAAAAGGGCTA; R: 
CTCCTACAGCTACCACAAATGC); hNDUFB8 (F: CCGCCAAGAAGTATAATATGCGT; 
R: TATCCACACGGTTCCTGTTGT); hNDUFB10 (F: AGCCCAATCCCATCGTCTACA; 
R: GCTGCCGCTCTATAAATTCTCT); pri/pre-let-7a (F: 
TGAGGTAGTAGGTTGTATAGTTTTAGGG; R: 
GGAAAGACAGTAGATTGTATAGTTATC); pri/pre-let-7b (Qiagen #MP00000028); pri/
pre-let-7c (Qiagen #MP00000035); pri/pre-let-7d (Qiagen #MP00000042); pri/pre-let-7e 
(Qiagen #MP00000049); pri/pre-let-7g (Qiagen #MP00000070); pri/pre-let-7i (Qiagen 
#MP00000077); let-7a (Qiagen #MS00032179); let-7b (Qiagen #MS00001225); let-7c 
(Qiagen #MS00005852); let-7d (Qiagen #MS00001232); let-7e (Qiagen #MS00032186); 
let-7f (Qiagen #MS00005866); let-7g (Qiagen #MS00010983); let-7i (Qiagen 
#MS00001253); U6 (Qiagen #MS00033740).
RNA Immunoprecipitation
FLAG-tagged LIN28A variants were purified using the protocol described earlier, with the 
following modifications: (i) Calyculin A was omitted; (ii) 100 U/ml RNasin (Promega) was 
included in the lysis and wash buffers; (iii) RNA was isolated from the beads by 
resuspension in Trizol (Invitrogen). Parental PA1 or HeLa Flp-In cells (no FLAG) were used 
as controls for antibody specificity. RNA purification and qRT-PCR were performed as 
described earlier. The ΔΔCt method was used to calculate enrichment, whereby RIP Ct 
values were normalized to the corresponding input and no-FLAG control Ct values. RNA-
seq was performed as described below.
RNA Sequencing
RNA >200 nt was isolated using Trizol (Invitrogen) combined with RNeasy columns 
(Qiagen). 50 ng purified RNA was subjected to polyA selection using the NEBNext Poly(A) 
mRNA Magnetic Isolation Module (NEB) and subsequently used for library preparation 
with the NEBNext Ultra RNA Library Prep Kit (NEB). Libraries were analyzed on a 
Bioanalyzer (Agilent) for quality control, quantified using the Qubit dsDNA HS Assay 
(Invitrogen) and qRT-PCR (Kapa Biosystems), and equimolar pools were sequenced on 
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HiSeq 2500 or NextSeq 500 instruments (Illumina) using 50-bp or 76-bp single-end 
protocols, respectively. Expression values (RPKM) were estimated using the TopHat39 and 
HTSeq-count tools40, and lowly expressed genes (RPKM≤10) were filtered out. Enrichment 
scores for each gene were calculated by dividing the RPKM value of the target protein RIP 
by the RPKM value of the no-FLAG control RIP after normalization of each RIP value to its 
respective input value.
Reprogramming
Reprogramming assays were performed essentially as described previously9. Briefly, dH1f 
fibroblasts were seeded at 2.5 × 105 cells/well in a 12-well plate and transduced overnight 
with a pool of lentiviral (OCT4, SOX2, NANOG) and retroviral (LIN28A variants) particles. 
Six days later, cells were trypsinized and 1–2 × 105 cells/well were re-plated onto MEF-
coated 12-well plates. Medium was switched to hESC medium and changed daily until day 
21 when reprogramming efficiency was measured. To do so, cells were fixed with 4% 
paraformaldehyde and stained with biotin-anti-TRA-1-60 (eBioscience #13-8863-82; 1:250) 
and streptavidin-HRP (Biolegend #405210; 1:500) primary and secondary antibodies, 
respectively. Staining was developed with the DAB Peroxidase kit (Vector Labs), and the 
number of iPSC colonies was quantified using ImageJ. Experiments were carried out and 
analyzed in a blinded manner.
Clonal Assay
mESCs maintained in 2i/LIF were seeded on MEF-coated 6-well plates at clonal density 
(500 cells/well) and allowed to grow for 5 days. At this point, cells were stained using the 
Leukocyte Alkaline Phosphatase kit (Sigma) and classified as showing either solid or mixed 
alkaline phosphatase staining by visual inspection, as described previously8.
Statistics and Reproducibility
All experiments were performed at least three independent times (unless noted otherwise) 
and respective data used for statistical analyses. Differences between groups were assessed 
using a two-tailed Student’s t-test in Microsoft Excel, with data assumed to fulfill t-test 
requirements. For RIP-seq analysis, differences were assessed using paired t-tests and the 
Benjamini-Hochberg correction for multiple hypotheses testing. Statistical significance is 
displayed as P<0.05 (one asterisk) or P<0.01 (two asterisks). Error bars indicate s.e.m. 
Sample sizes and reproducibility for each experiment are described in the respective figure 
legends, and raw data from independent replicates are provided in Supplementary Table 4.
Data Availability
RNA-sequencing data that support the findings of this study have been deposited in the Gene 
Expression Omnibus (GEO) under accession code GSE83906. Proteomics data have been 
deposited in the Mass spectrometry Interactive Virtual Environment (MassIVE) under ID# 
MSV000080302. All other data supporting the findings of this study are available from the 
corresponding author upon reasonable request.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MAPK/ERK phosphorylates LIN28A on S200
(a) Schematic of the LIN28A domain structure with indicated phosphorylation sites, as 
mapped by mass spectrometry. Respective motifs and homologous sequences across several 
mammalian species are shown below each site. CSD = cold-shock domain; NLS = nuclear 
localization signal; CCHC = zinc finger domains.
(b) Representative phosphopeptide MS/MS spectrum for S200.
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(c) Western blot analysis of LIN28A (S200) phosphorylation in HeLa cells stably expressing 
wild-type (WT) or phospho-null (S200A) FLAG-LIN28A. A representative image of three 
independent experiments is shown.
(d) Western blot analysis of LIN28A (S200) phosphorylation in PA1 hECCs after 60-min 
treatment with a panel of inhibitors of proline-directed kinases. Tn1 = Torin1 (100 nM); PD 
= PD0325901 (1 µM); SB = SB203580 (2 µM); SP = SP600125 (20 µM); Ken = 
Kenpaullone (5 µM). Quantification of Western blot data is shown on top. n=3 independent 
experiments. Error bars represent s.e.m. *P < 0.05 (two-tailed Student’s t-test).
(e) Western blot analysis of LIN28A (S200) phosphorylation in PA1 cells after 30-min pre-
treatment with DMSO, PD0325901 (1 µM), or SB203580 (2 µM), followed by 30-min 
treatment with DMSO or PMA (200 nM). Cells were serum-starved for 16–20 h prior to 
addition of inhibitors. A representative image of two independent experiments is shown.
(f) Western blot analysis of LIN28A (S200) phosphorylation in 293T cells stably expressing 
wild-type FLAG-LIN28A after transfection with RFP, wild-type (WT), constitutively active 
(R4F), or kinase-dead (K97M) MEK1. Cells were transfected, incubated for 48 h, and then 
serum-starved for 16–20 h prior to analysis. A representative image of two independent 
experiments is shown.
(g) Western blot analysis of LIN28A (S200) phosphorylation in PA1 cells after 30-min 
stimulation with serum (10%), fibroblast growth factor (FGF) (100 ng/ul), or epidermal 
growth factor (EGF) (100 ng/ul). Cells were serum-starved for 16–20 h prior to stimulation. 
A representative image of two independent experiments is shown. Statistics source data are 
shown in Supplementary Table 4. Unprocessed scans of blots are shown in Supplementary 
Fig. 5.
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Figure 2. LIN28A phosphorylation increases its protein stability
(a) Western blot analysis of transgenic FLAG-LIN28A in iLIN28A mESCs after 30-min 
treatment with DMSO or Calyculin A (100 nM). A representative image of three 
independent experiments is shown.
(b) Western blot (left) and qRT-PCR (right) analysis of endogenous LIN28A in PA1 cells 
after three-hour treatment with DMSO or PMA (200 nM). Cells were serum-starved for 16–
20 h prior to addition of drugs. n=3 independent experiments. Error bars represent s.e.m. n.s. 
= non-significant; P=0.09 (two-tailed Student’s t-test).
(c) Western blot (left) and qRT-PCR (right) analysis of endogenous LIN28A in PA1 cells 
after 48-hour treatment with DMSO or PD0325901 (1 µM). n=3 independent experiments. 
Error bars represent s.e.m. n.s. = non-significant; P=0.79 (two-tailed Student’s t-test).
(d) Western blot (left) and qRT-PCR (right) analysis of transgenic FLAG-LIN28A in 
isogenic 293T (RMCE) or HeLa (Flp-In) cells. Cells were engineered to stably express a 
single copy of the respective LIN28A variant: wild-type (WT), phospho-mimetic (S200D or 
S200E), or phospho-null (S200A). n=3 independent experiments. Error bars represent s.e.m. 
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P=0.77 (S200D) and P=0.70 (S200A) for 293T; P=0.42 (S200E) and P=0.48 (S200A) for 
HeLa (two-tailed Student’s t-test).
(e) Cycloheximide chase of endogenous phospho- and total LIN28A in PA1 cells. CHX = 
cycloheximide (100 µg/ml). A representative image of two independent experiments is 
shown.
(f) Cycloheximide chase of transgenic FLAG-LIN28A variants in HeLa (Flp-In) cells. CHX 
= cycloheximide (100 µg/ml). A representative image of two independent experiments is 
shown.
(g) Chase of transgenic FLAG-LIN28A variants after Dox withdrawal (Dox OFF) in HeLa 
(Flp-In) cells. Dox = doxycycline (100 ng/ml). A representative image of two independent 
experiments is shown. Statistics source data are shown in Supplementary Table 4. 
Unprocessed scans of blots are shown in Supplementary Fig. 5.
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Figure 3. LIN28A phosphorylation can uncouple its let-7-dependent and independent activities
(a) Western blot analysis of RNA immunoprecipitation in PA1 cells overexpressing wild-
type (WT) or phospho-mimetic (S200D) FLAG-LIN28A. A representative image of four 
independent experiments is shown.
(b) qRT-PCR analysis of pri/pre-let-7 species immunoprecipitated by wild-type (WT) or 
phospho-mimetic (S200D) FLAG-LIN28A in PA1 cells. n=4 independent experiments. Data 
were normalized to cell number prior to RT. Error bars represent s.e.m. *P<0.05 (two-tailed 
Student’s t-test, S200D vs. WT).
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(c) qRT-PCR analysis of mature let-7 species in PA1 cells stably overexpressing wild-type 
(WT) or phospho-mimetic (S200D) FLAG-LIN28A. n=3 independent experiments. Error 
bars represent s.e.m. P>0.05 (two-tailed Student’s t-test, S200D vs. WT).
(d) RNA-seq analysis of mRNAs immunoprecipitated by wild-type (WT) or phospho-
mimetic (S200D) FLAG-LIN28A in PA1 cells. Each dot represents an average enrichment 
value for transcripts from a given gene. n=3 independent experiments. Data were normalized 
to the amount of immunoprecipitated LIN28A prior to sequencing. Detailed description of 
the analysis is provided in the Methods section and the complete data set is available in 
Supplementary Table 2.
(e) qRT-PCR analysis of representative mRNA targets immunoprecipitated by wild-type 
(WT) or phospho-mimetic (S200D) FLAG-LIN28A in PA1 cells. n=4 independent 
experiments. Data were normalized to cell number prior to RT. Error bars represent s.e.m. 
*P<0.05 (two-tailed Student’s t-test, S200D vs. WT).
(f) qRT-PCR analysis of representative mRNA targets in PA1 cells stably expressing wild-
type (WT) or phospho-mimetic (S200D) FLAG-LIN28A. n=3 independent experiments. 
Error bars represent s.e.m. P>0.05 (two-tailed Student’s t-test, S200D vs. WT).
(g) Western blot analysis of representative mRNA targets in PA1 cells stably expressing 
wild-type (WT) or phospho-mimetic (S200D) FLAG-LIN28A. A representative image of 
three independent experiments is shown. Statistics source data are shown in Supplementary 
Table 4. Unprocessed scans of blots are shown in Supplementary Fig. 5.
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Figure 4. LIN28A phosphorylation contributes to the regulation of pluripotency transitions
(a) Western blot (left) and qRT-PCR (right) analysis of wild-type (WT), phospho-null 
(S200A), and phospho-mimetic (S200D) FLAG-LIN28A at day 6 of reprogramming. n=4 
independent experiments. Error bars represent s.e.m. P=0.10 (S200A) and P=0.52 (S200D) 
(two-tailed Student’s t-test vs. WT).
(b) Levels of mature let-7s at day 6 of reprogramming using respective LIN28A constructs. 
EV = empty vector. n=4 independent experiments. Error bars represent s.e.m. P>0.05 (two-
tailed Student’s t-test vs. WT).
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(c) TRA-1-60 staining of iPSCs harboring empty vector (EV), wild-type (WT), phospho-null 
(S200A), or phospho-mimetic (S200D) FLAG-LIN28A (day 21 of reprogramming). 
Quantification of reprogramming efficiency based on the number of TRA-1-60+ colonies is 
shown on the right. n=4 independent experiments. Error bars represent s.e.m. *P<0.05 (two-
tailed Student’s t-test vs. WT).
(d) Western blot (left) and qRT-PCR (right) analysis of endogenous LIN28A in v6.5 mESCs 
cultured in serum/LIF or 2i/LIF. n=3 independent experiments. Error bars represent s.e.m. 
*P<0.05 (two-tailed Student’s t-test).
(e) Western blot (left) and qRT-PCR (right) analysis of endogenous LIN28A in v6.5 mESCs 
after a four-hour dropout of PD0325901 (PD) or CHIR99021 (CH). n=3 independent 
experiments. Error bars represent s.e.m. P=0.99 (PD) and P=0.89 (CH) (two-tailed Student’s 
t-test vs. PD+CH).
(f) Western blot (left) and qRT-PCR (right) analysis of transgenic wild-type (WT), phospho-
mimetic (S200D), or phospho-null (S200A) FLAG-LIN28A added back in LIN28A/B KO 
mESCs. n=3 independent experiments. Error bars represent s.e.m. P=0.63 (S200D) and 
P=0.60 (S200A) (two-tailed Student’s t-test vs. WT).
(g) Alkaline Phosphatase (AP) analysis of mESCs from panel (f) grown at clonal density 
upon transfer from 2i/LIF to serum/LIF. Representative images of colonies with solid and 
mixed staining patterns are shown on the left. Scale bar = 100 µm. Quantification of the 
fraction of solid colonies is shown on the right. n=4 independent experiments. Error bars 
represent s.e.m. **P<0.01 (two-tailed Student’s t-test). Statistics source data are shown in 
Supplementary Table 4. Unprocessed scans of blots are shown in Supplementary Fig. 5.
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